JP2023525100A - Ｃｒａｆ阻害剤を含む治療的組み合わせ - Google Patents

Ｃｒａｆ阻害剤を含む治療的組み合わせ Download PDF

Info

Publication number
JP2023525100A
JP2023525100A JP2022568601A JP2022568601A JP2023525100A JP 2023525100 A JP2023525100 A JP 2023525100A JP 2022568601 A JP2022568601 A JP 2022568601A JP 2022568601 A JP2022568601 A JP 2022568601A JP 2023525100 A JP2023525100 A JP 2023525100A
Authority
JP
Japan
Prior art keywords
melanoma
compound
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525100A5 (https=
Inventor
カポニグロ，ジオルダノ
クック，ヴェセリナ
マーティン スタンベルガー，ウーツ
スチュアート，ダリン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2023525100A publication Critical patent/JP2023525100A/ja
Publication of JP2023525100A5 publication Critical patent/JP2023525100A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022568601A 2020-05-12 2021-05-11 Ｃｒａｆ阻害剤を含む治療的組み合わせ Pending JP2023525100A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023470P 2020-05-12 2020-05-12
US63/023,470 2020-05-12
PCT/IB2021/054013 WO2021229439A1 (en) 2020-05-12 2021-05-11 Therapeutic combinations comprising a craf inhibitor

Publications (2)

Publication Number Publication Date
JP2023525100A true JP2023525100A (ja) 2023-06-14
JP2023525100A5 JP2023525100A5 (https=) 2024-05-21

Family

ID=75954158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568601A Pending JP2023525100A (ja) 2020-05-12 2021-05-11 Ｃｒａｆ阻害剤を含む治療的組み合わせ

Country Status (6)

Country Link
US (1) US20240000789A1 (https=)
EP (1) EP4149472A1 (https=)
JP (1) JP2023525100A (https=)
CN (1) CN115551509A (https=)
TW (1) TW202207942A (https=)
WO (1) WO2021229439A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2024148307A1 (en) * 2023-01-06 2024-07-11 Erasca, Inc. Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051306A1 (en) * 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
WO2018203219A1 (en) * 2017-05-02 2018-11-08 Novartis Ag Combination therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1761528T1 (sl) 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
GB0719771D0 (en) * 2007-10-10 2007-11-21 Therapeutics Ltd E Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
KR20190057421A (ko) * 2012-08-17 2019-05-28 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN111053768B (zh) * 2013-07-12 2023-12-12 皮拉马尔企业有限公司 用于治疗黑素瘤的药物组合
AP2016009099A0 (en) 2013-11-01 2016-03-31 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
PL3319993T3 (pl) * 2015-07-10 2020-07-27 Genmab A/S Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka
EP3340987A1 (en) * 2015-08-28 2018-07-04 Novartis AG Combination of ribociclib and dabrafenib for treating or preventing cancer
TW202023556A (zh) * 2018-08-27 2020-07-01 美商庫拉腫瘤技術股份有限公司 以mapk路徑抑制劑治療腺癌
CA3123510A1 (en) * 2018-12-20 2020-06-25 Novartis Ag Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer
EP4106756A1 (en) * 2020-02-18 2022-12-28 Novartis AG Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051306A1 (en) * 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
WO2018203219A1 (en) * 2017-05-02 2018-11-08 Novartis Ag Combination therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Record History: NCT02974725, A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma", CLINICALTRIALS.GOV ARCHIVE [ONLINE], JPN6025024979, 17 January 2019 (2019-01-17), pages 2025 - 06, ISSN: 0005758746 *

Also Published As

Publication number Publication date
TW202207942A (zh) 2022-03-01
US20240000789A1 (en) 2024-01-04
WO2021229439A1 (en) 2021-11-18
CN115551509A (zh) 2022-12-30
EP4149472A1 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
JP7520189B2 (ja) 組み合わせ療法
JP7114575B2 (ja) Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ
JP2023525100A (ja) Ｃｒａｆ阻害剤を含む治療的組み合わせ
KR20180041677A (ko) Mdm2 억제제 및 그의 조합물
CA2914310A1 (en) Pharmaceutical combinations
JP2022514056A (ja) 癌の治療に使用するためのＲａｆ阻害剤及びＣＤＫ４／６阻害剤による組み合わせ療法
US20230226030A1 (en) Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
AU2022320615B2 (en) 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
EP4203963B1 (en) Combination therapy of naporafenib and trametinib for use in the treatment of sarcoma
US20240173293A1 (en) Treatment of Breast Cancer with Amcenestrant and Palbociclib
JP7709959B2 (ja) 連続的な治療設定における免疫チェックポイント阻害剤に対する患者の応答を高めるためのｆｇｆｒ遺伝子改変癌におけるｆｇｆｒ阻害剤の使用
HK40086978A (zh) 包含craf抑制剂的治疗组合
EP4504202B1 (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
KR20150003786A (ko) Pi3k 저해제 및 mek 저해제를 이용한 암 치료 방법
JP2022547311A (ja) 骨髄線維症の治療のためのｍｄｍ２阻害剤の使用
TW202404599A (zh) 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法
TW202508598A (zh) 癌症療法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240510

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20241218

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250922

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260417